Palisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules

May 7, 2024

https://www.globenewswire.com/news-release/2024/05/07/2876616/0/en/Palisade-Bio-Announces-Closing-of-4-Million-Private-Placement-Priced-At-The-Market-Under-Nasdaq-Rules.html

Carlsbad, CA, May 07, 2024 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq:PALI), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, is announcing today that it has closed its previously announced private placement with an institutional investor for the purchase of 615,242 shares of common stock (or certain pre-funded warrants in lieu thereof) for gross proceeds of approximately $4 million, before deducting placement agent fees and other offering expenses payable by the Company.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.